Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Version of Record online: 27 MAY 2014
© 2014 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 275, Issue 6, pages 551–561, June 2014
How to Cite
Erasmus Medical Center, Rotterdam, the Netherlands; University of Messina, Messina, Italy; Università Milano-Bicocca, Milan, Italy; Brighton Collaboration Foundation, Basel, Switzerland; University Children's Hospital Basel, University of Basel, Basel, Switzerland; Janssen Research and Development LLC, Titusville, NJ, USA; Foundation for the National Institutes of Health, Bethesda, MD, USA). Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?. (Review) J Intern Med 2014; 275: 551–561., , , , , , , , , (
- Issue online: 27 MAY 2014
- Version of Record online: 27 MAY 2014
- Accepted manuscript online: 17 MAR 2014 10:57AM EST
- 1Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20(Suppl. C): C40–4..
- 2Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16: 359–65., .
- 3Improving reporting of adverse drug reactions: systematic review. Clin Epidemiol 2009; 1: 75–92., , .
- 4Use of health care databases in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 311–13..
- 5Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419–25., .
- 6Primer: administrative health databases in observational studies of drug effects–advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725–32., .
- 7Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997; 99: 765–73., , et al.
- 8The new Sentinel Network–improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645–7., , , , , .
- 9Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration. Med Care 2012; 50: 948–53., , , , , .
- 10The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012; 21(Suppl. 1): 1–8., , et al.
- 11The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012; 21(Suppl. 1): 291–7., , , .
- 12Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153: 600–6., , et al.
- 13Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011; 20: 1–11., , et al.
- 14I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill 2012; 17: 1–2., .
- 15Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011; 343: d3908., , , , , .
- 16The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31: 1246–54., , et al.
- 17CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med 2012; 6: e134–40., , et al.
- 18The changing privacy landscape in the era of big data. Mol Syst Biol 2012; 8: 612..
- 19Pharmacovigilance in perspective. Drug Saf 1999; 21: 429–47., , , .
- 20Re-use of Mini-Sentinel data following rapid assessments of potential safety signals using customizable modular programs. Available from: http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_Methods_Re-use-of-Mini-Sentinel-Data.pdf.
- 21VAESCO Consortium. Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigationSeptember 2012: Available from: http://www.ecdc.europa.eu/en/publications/publications/vaesco%20report%20final%20with%20cover.pdf.
- 22Drug safety reform at the FDA–pendulum swing or systematic improvement? N Engl J Med 2007; 356: 1700–2..
- 23Database size and power to detect safety signals in pharmacovigilance. Expert Opin Drug Saf 2007; 6: 713–21., , , .
- 24Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf 2012; 21: 611–21., , et al.
- 25A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine 2012; 30: 3042–6., , et al.
- 26Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2012; 21: 690–6., , , , .
- 27Drug use in children: cohort study in three European countries. BMJ 2008; 337: a2245., , et al.
- 28Mini-Sentinel. Overview and Description of the Common Data Model v2.1. 2012; Available from: http://www.mini-sentinel.org/work_products/Data_Activities/Mini-Sentinel_Common-Data-Model_v2.1.pdf.
- 29Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012; 19: 54–60., , , , .
- 30OMOP. Observational Medical Outcomes Partnership Common Data Model Specifications Version 4.0. Available from: http://omop.fnih.org/CDMvocabV4.
- 31Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 2012; 45: 689–96., , , .
- 32Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf 2009; 18: 1176–84., , et al.
- 33The unified medical language system. Methods Inf Med 1993; 32: 281–91., , .
- 34Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc 2013; 20: 184–92., , et al.